The Middle East tumor ablation market size was estimated at USD 50.5 million in 2024 and is projected to reach USD 95.2 million in 2030, growing at a CAGR of 11.1% from 2025 to 2030. The cancer burden in the region, along with increased investments in oncology and the rising demand for non-invasive treatment methods, are the major factors driving this market's growth. The demand for new local treatments using such methods as radiofrequency, microwave, cryoablation, or irreversible electroporation is growing as medical workers look for safer and more effective treatment methods for cancer.
According to a study published in September 2024 by John Wiley & Sons, Inc., the Gulf Cooperation Council (GCC) countries registered 42,475 new cancer cases and 19,895 deaths in 2020. The cancer incidence is predicted to increase by 116% in Saudi Arabia and by up to 270% in Qatar by 2040. This alarming increase underscores the growing need for efficient and less-invasive cancer therapies. Tumor abolition methods that enable the targeted destruction of tumors, with less time needed for recovery and reduced hospital stays, are becoming more popular in the Middle East. As governments and private medical establishments continue to invest in advanced oncology centers and widen the scope of interventional radiology, the Middle East tumor ablation industry will be experiencing high growth in the near future.
Moreover, cancer hospitals and oncology networks, which are often financed by governments and large private healthcare groups in the Middle East, are expanding their capacity, thereby creating a demand for image-guided ablation services. For instance, The Hamdan Bin Rashid Cancer Hospital in Dubai is scheduled to launch in 2026 as part of Dubai Health’s academic health system. In June 2024, Dubai Health collaborated with The Royal Marsden NHS Foundation Trust to expedite clinical development and establish first-class cancer care and research facilities in the region.
Physicians are progressively choosing tumor ablation to treat liver, kidney, lung, and bone tumors as this method is said to be more beneficial than surgery in terms of a shorter hospital stay, quicker recovery, and it is a viable solution when surgery cannot be done. These reasons are attractive to both patients and healthcare payers seeking cost-efficient, high-quality outcomes. Technological advances, such as the reduction in size of ablation probes, the increased speed of the energy delivery system, the enhancement of imaging guidance, and the growing popularity of interventional radiology training, are making operations safer, more accurate, and more reliable. All these factors together enhance the region’s capacity to deliver state-of-the-art, minimally invasive cancer treatments, making tumor ablation a crucial element of modern oncology care.
This product will be delivered within 1-3 business days.
According to a study published in September 2024 by John Wiley & Sons, Inc., the Gulf Cooperation Council (GCC) countries registered 42,475 new cancer cases and 19,895 deaths in 2020. The cancer incidence is predicted to increase by 116% in Saudi Arabia and by up to 270% in Qatar by 2040. This alarming increase underscores the growing need for efficient and less-invasive cancer therapies. Tumor abolition methods that enable the targeted destruction of tumors, with less time needed for recovery and reduced hospital stays, are becoming more popular in the Middle East. As governments and private medical establishments continue to invest in advanced oncology centers and widen the scope of interventional radiology, the Middle East tumor ablation industry will be experiencing high growth in the near future.
Moreover, cancer hospitals and oncology networks, which are often financed by governments and large private healthcare groups in the Middle East, are expanding their capacity, thereby creating a demand for image-guided ablation services. For instance, The Hamdan Bin Rashid Cancer Hospital in Dubai is scheduled to launch in 2026 as part of Dubai Health’s academic health system. In June 2024, Dubai Health collaborated with The Royal Marsden NHS Foundation Trust to expedite clinical development and establish first-class cancer care and research facilities in the region.
Physicians are progressively choosing tumor ablation to treat liver, kidney, lung, and bone tumors as this method is said to be more beneficial than surgery in terms of a shorter hospital stay, quicker recovery, and it is a viable solution when surgery cannot be done. These reasons are attractive to both patients and healthcare payers seeking cost-efficient, high-quality outcomes. Technological advances, such as the reduction in size of ablation probes, the increased speed of the energy delivery system, the enhancement of imaging guidance, and the growing popularity of interventional radiology training, are making operations safer, more accurate, and more reliable. All these factors together enhance the region’s capacity to deliver state-of-the-art, minimally invasive cancer treatments, making tumor ablation a crucial element of modern oncology care.
Middle East Tumor Ablation Market Report Segmentation
This report forecasts revenue growth at country levels and analyzes the latest industry trends in each sub-segments from 2021 to 2030. For this study, the analyst has segmented the Middle East tumor ablation market report based on technology, treatment, and application.Technology Outlook (Revenue, USD Million, 2021-2030)
- Radiofrequency Ablation
- Microwave Ablation
- Cryoablation
- Irreversible Electroporation Ablation
- HIFU
- Other Ablation Technologies
Treatment Outlook (Revenue, USD Million, 2021-2030)
- Surgical Ablation
- Laparoscopic Ablation
- Percutaneous Ablation
Application Outlook (Revenue, USD Million, 2021-2030)
- Kidney Cancer
- Liver Cancer
- Breast Cancer
- Lung Cancer
- Prostate Cancer
- Other Cancer
Region Outlook (Revenue, USD Million, 2021-2030)
- Middle East
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Middle East Tumor Ablation Market Variables, Trends, & Scope
Chapter 4. Middle East Tumor Ablation Market: Technology Estimates & Trend Analysis
Chapter 5. Middle East Tumor Ablation Market: Treatment Estimates & Trend Analysis
Chapter 6. Middle East Tumor Ablation Market: Application Estimates & Trend Analysis
Chapter 7. Middle East Tumor Ablation Market: Regional Estimates & Trend Analysis
Chapter 8. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
The key companies profiled in this Middle East Tumor Ablation market report include:- Medtronic plc.
- Boston Scientific Corporation
- Johnson & Johnson Service Inc. (Ethicon, Inc.)
- AngioDynamics
- Bioventus Inc. (Misonix Inc.)
- EDAP TMS
- Chongqing Haifu Medical Technology Co., Ltd
- Mermaid Medical
- HealthTronics, Inc.
- H.S. Hospital Service S.p.A
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 175 |
| Published | November 2025 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 50.5 Million |
| Forecasted Market Value ( USD | $ 95.2 Million |
| Compound Annual Growth Rate | 11.1% |
| Regions Covered | Middle East |
| No. of Companies Mentioned | 11 |
